V
Vyome Holdings, Inc. (HIND)
NCM – Real vaqt narxi. Valyuta: USD
2.01
+0.02 (1.01%)
Yopilishda: Jul 30, 2026, 1:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
2.01
+0.02 (1.01%)
Yopilishda: Jul 30, 2026, 1:59 PM EDT
Vyome Holdings, Inc., klinik bosqichdagi ixtisoslashtirilgan farmatsevtika kompaniyasi, Qo'shma Shtatlarda immuno-yallig'lanish va kam uchraydigan kasalliklarga qaratilgan terapevtik mahsulotlarni ishlab chiqadi. U Farmatsevtika va Biotexnologiya segmentlari orqali faoliyat yuritadi. Kompaniyaning asosiy mahsulot nomzodi VT-1953, mahalliy gel shaklidagi qo'sh DNA Giraza/Topoisomerase ingibitori va immunomodulyatori, bakterial kon'yunktivitni davolash uchun 2-bosqichli klinik bosqichda. Kompaniyaning ko'z uchun immunitet-yallig'lanish holatlarini davolash uchun inozin 5′-monofosfat dehidrogenaza ferment ingibitori bo'lgan mahalliy ko'z tomchisi VT-1908; va yallig'lanishli akne davolash uchun 2-bosqichli klinik bosqichda bo'lgan VB-1953 ni ham ishlab chiqadi. Bundan tashqari, kompaniya molekulyar almashtirish terapiyasi (MRT) platformasidan foydalangan holda antifungal mahsulotlarni ishlab chiqadi. Kompaniyaning keyingi avlod antifungal mahsulotlarini ishlab chiqish va tijoratlashtirish uchun Sun Pharma Laboratories Limited bilan hamkorlik va litsenziya shartnomasi mavjud. Kompaniya Kembrij, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Charles G. Chavdarian Ph.D. | Senior Vice President of Product Development & Regulatory CMC |
| Dr. Richard Fahrner Ph.D. | Chief Technology Officer |
| Dr. Shiladitya Sengupta M.Sc., Ph.D. | Co-Founder, Director and Member of Scientific & Clinical Advisory Board |
| Dr. Tamara Agajanov M.D. | Senior Vice President of Clinical Development |
| Mr. Jules Abraham | Investor Relations Officer |
| Mr. Robert Dickey IV | Chief Financial Officer |
| Mr. Venkateswarlu Nelabhotla M.B.A. | Co-Founder, CEO, President & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-29 | 8-K | ea0292643-8k_vyome.htm |
| 2026-05-12 | 10-Q | ea0289466-10q_vyome.htm |
| 2026-04-29 | 8-K | ea0288267-8k_vyome.htm |
| 2026-03-31 | DEF 14A | ea0282811-02.htm |
| 2026-03-20 | PRE 14A | ea0282811-pre14a_vyome.htm |
| 2026-03-18 | 10-K | ea0280821-10k_vyomehold.htm |
| 2026-02-25 | 8-K | ea0277935-8k_vyome.htm |
| 2026-02-13 | 8-K | ea0276975-8k_vyome.htm |
| 2026-01-28 | 8-K | ea0274367-8k_vyome.htm |
| 2025-12-23 | 8-K | ea0270832-8k_vyome.htm |